Twitter LinkedIn
Return to Wellspring


MITO-DCA - Mitochondria-Targeted Delivery of Anti-Cancer Drug DCA


Project TitleMITO-DCA - Mitochondria-Targeted Delivery of Anti-Cancer Drug DCA
Track Code2061
Short Description

The invention is comprised of a composition of matter and method of use of that composition. The new molecule, a targeting prodrug, is a combination of the orphan drug dichloroacetate (DCA) with mitochondrial drug targeting moiety, triphenyl phosphonium (TPP) with a biodegradable linker into one single molecule. Preliminary studies of DCA have demonstrated that it has the potential to become a major player in the field of cancer chemotherapy.  It is a mitochondrial kinase inhibitor that plays a crucial role in switching cancer specific metabolism from cytoplasmic glycolysis to mitochondrial oxidative phosphorylation.  However, a major obstacle for DCA in the clinic is that high concentrations are needed due to poor update and limited bioavailability


To address that high-concentration and limited bioavailability issues, Dr. Shanta Dhar has developed a simple programmable platform for construction of a targeted multiple DCA-loaded compound “MITO-DCA” with remarkable cancer-cell specific activity and anti-tumor immunity.  Incorporation of a lipophilic TPP cation through a biodegradable linker to conjugate multiple DCA moieties in MITO-DCA allowed for targeting of cancer cell mitochondria, which results glycolysis inhibition and an anti-tumor immune response. In vitro results are promising.

References and Intellectual Property


Tagscancer therapeutic, drug delivery, nanomedicine
Posted DateNov 14, 2017 1:09 PM


Rachael Widener


File Name Description
2061 Dhar RW.doc None Download